{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:36:02Z","timestamp":1791171362620,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T00:00:00Z","timestamp":1395273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"DOI":"10.1007\/s00520-014-2196-1","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T23:26:14Z","timestamp":1395185174000},"source":"Crossref","is-referenced-by-count":2,"title":["Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor"],"prefix":"10.1007","author":[{"given":"Nelson","family":"Hamerschlak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmino","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L\u00facia","family":"Cornacchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merula","family":"Steagall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,20]]},"reference":[{"issue":"10","key":"2196_CR1","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"S Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10):1880\u20131885","journal-title":"Blood"},{"issue":"8","key":"2196_CR2","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","volume":"112","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M et al (2008) Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112(8):3500\u20133507","journal-title":"Blood"},{"issue":"4","key":"2196_CR3","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.12968\/bjon.2012.21.Sup4.S16","volume":"21","author":"M Dowling","year":"2012","unstructured":"Dowling M, Meenaghan T, Kelly M (2012) Treating chronic myeloid leukaemia: NICE guidance. Br J Nurs 21(4):S16\u2013S17","journal-title":"Br J Nurs"},{"issue":"3","key":"2196_CR4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.32635\/2176-9745.RBC.2002v48n3.2219","volume":"48","author":"JA Dobbin","year":"2002","unstructured":"Dobbin JA, Gadelha MIP (2002) Mesilato de Imatinibe para tratamento da leucemia miel\u00f3ide cr\u00f4nica [Imatinib Mesylate in the treatment of chronic myelogenous leukemia]. Rev Bras Cancerol 48(3):429\u2013438","journal-title":"Rev Bras Cancerol"},{"issue":"11","key":"2196_CR5","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F et al (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21(11):2138\u20132146","journal-title":"J Clin Oncol"},{"issue":"2","key":"2196_CR6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2011.02.007","volume":"81","author":"F Efficace","year":"2012","unstructured":"Efficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M et al (2012) Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 81(2):123\u2013135","journal-title":"Crit Rev Oncol Hematol"},{"key":"2196_CR7","unstructured":"Hamerschlak N, Pietrocola M, Tabak D, Lerner D, Chiattone C, Hungria V, et al (2003) Treatment of accelerated (AP) and blastic phase (BP) of Philadelphia (Ph) chromosome positive chronic myeloid leukemia (CML) with imatinib. Proc Am Soc Clin Oncol 22:(abstr 2479). Available from: http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=103947 . Accessed in 2012 (Aug 28)"},{"issue":"21","key":"2196_CR8","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1002\/cncr.25273","volume":"116","author":"J Cortes","year":"2010","unstructured":"Cortes J, De Souza C, Ayala-Sanchez M, Bendit I, Best-Aguilera C, Enrico A et al (2010) Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer 116(21):4991\u20135000","journal-title":"Cancer"},{"issue":"24","key":"2196_CR9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251\u20132259","journal-title":"N Engl J Med"},{"issue":"24","key":"2196_CR10","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260\u20132270","journal-title":"N Engl J Med"},{"key":"2196_CR11","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes JE, Shah S, Ayala M, et al (2010) Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study. Journal of Clinical Oncology 28(18 Suppl):LBA6500. Available from: http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/28\/18_suppl\/LBA6500 . Accessed in 2012 (Aug 28)"},{"issue":"24","key":"2196_CR12","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251\u20132259","journal-title":"N Engl J Med"},{"key":"2196_CR13","doi-asserted-by":"crossref","unstructured":"Larson RA, le Coutre PD, Reiffers J, Hughes TP, Saglio G, Edrich P, et al (2010) Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year. Journal of Clinical Oncology 28(15 Suppl):6501. Available from: http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/28\/15_suppl\/6501 . Accessed in 2012 (Aug 28)","DOI":"10.1200\/jco.2010.28.15_suppl.6501"},{"key":"2196_CR14","unstructured":"Terasawa T, Dahabreh I, Trikalinos TA (2010) BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors inpatients with chronic myeloid leukemia. Version 2. PLoS Curr 2:RRN1204"},{"issue":"4","key":"2196_CR15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","volume":"117","author":"J Pinilla-Ibarz","year":"2011","unstructured":"Pinilla-Ibarz J, Cortes J, Mauro MJ (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 117(4):688\u2013697","journal-title":"Cancer"},{"issue":"5","key":"2196_CR16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","volume":"117","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Cortes J, Kantarjian H (2011) Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 117(5):897\u2013906","journal-title":"Cancer"},{"issue":"3","key":"2196_CR17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2005.03.2011","volume":"24","author":"I Iacobucci","year":"2006","unstructured":"Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D et al (2006) Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1\u00a0year of imatinib therapy and those who achieved such a response after 12\u00a0months of treatment. J Clin Oncol 24(3):454\u2013459","journal-title":"J Clin Oncol"},{"issue":"25","key":"2196_CR18","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D et al (2009) Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25):6315\u20136321","journal-title":"Blood"},{"issue":"13","key":"2196_CR19","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1001\/jama.1992.03490130122041","volume":"268","author":"ED Pellegrino","year":"1992","unstructured":"Pellegrino ED (1992) Is truth telling to the patient a cultural artifact? JAMA 268(13):1734\u20131735","journal-title":"JAMA"},{"key":"2196_CR20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1749-6632.1997.tb48079.x","volume":"809","author":"SL Faria","year":"1997","unstructured":"Faria SL, Souhami L (1997) Communication with the cancer patient. Information and truth in Brazil. Ann N Y Acad Sci 809:163\u2013171","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2196_CR21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1590\/S0104-42302004000100033","volume":"50","author":"A Gulinelli","year":"2004","unstructured":"Gulinelli A, Aisawa RK, Konno SN, Morinaga CV, Costardi WL, Antonio RO et al (2004) Desejo de informa\u00e7\u00e3o e participa\u00e7\u00e3o nas decis\u00f5es terap\u00eauticas em caso de doen\u00e7as graves em pacientes atendidos em um hospital universit\u00e1rio [Desire of information and participation in therapeutic decisions concerning severe diseases, in patients of a University Hospital]. Rev Assoc Med Bras 50(1):41\u201347","journal-title":"Rev Assoc Med Bras"},{"key":"2196_CR22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1749-6632.1997.tb48101.x","volume":"809","author":"GA Rigatos","year":"1997","unstructured":"Rigatos GA (1997) Cancer and truth-telling in Greece. Historical, statistical, and clinical data. Ann N Y Acad Sci 809:383\u2013392","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"2196_CR23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00005650-198807000-00002","volume":"26","author":"JA Hall","year":"1988","unstructured":"Hall JA, Roter DL, Katz NR (1988) Meta-analysis of correlates of provider behavior in medical encounters. Med Care 26(7):657\u2013675","journal-title":"Med Care"},{"issue":"5\u20136","key":"2196_CR24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/1467-8519.00357","volume":"17","author":"CH Silva Da","year":"2003","unstructured":"Da Silva CH, Cunha RL, Tonaco RB, Cunha TM, Diniz AC, Domingos GG et al (2003) Not telling the truth in the patient- physician relationship. Bioethics 17(5\u20136):417\u2013424","journal-title":"Bioethics"},{"issue":"1","key":"2196_CR25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/0003-4819-108-1-125","volume":"108","author":"AL Suchman","year":"1988","unstructured":"Suchman AL, Matthews DA (1988) What makes the patient-doctor relationship therapeutic? Exploring the connexional dimension of medical care. Ann Intern Med 108(1):125\u2013130","journal-title":"Ann Intern Med"},{"issue":"2","key":"2196_CR26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/jnr.0b013e318257b5e0","volume":"20","author":"Z Farsi","year":"2012","unstructured":"Farsi Z, Nayeri ND, Negarandeh R (2012) The coping process in adults with acute leukemia undergoing hematopoietic stem cell transplantation. J Nurs Res 20(2):99\u2013109","journal-title":"J Nurs Res"},{"issue":"11","key":"2196_CR27","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s00520-012-1389-8","volume":"20","author":"M Grant","year":"2012","unstructured":"Grant M, Cooke L, Williams AC, Bhatia S, Popplewell L, Uman G, Forman S (2012) Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics. Support Care Cancer 20(11):2697\u20132704","journal-title":"Support Care Cancer"},{"issue":"2","key":"2196_CR28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clml.2011.10.004","volume":"12","author":"S Holloway","year":"2012","unstructured":"Holloway S, Lord K, Bethelmie-Bryan B, Shepard MW, Neely J, McLemore M et al (2012) Managing chronic myeloid leukemia: a coordinated team care perspective. Clin Lymphoma Myeloma Leuk 12(2):88\u201393","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2196_CR29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1524-4733.2005.08202.x","volume":"8","author":"KJ Yost","year":"2005","unstructured":"Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D (2005) Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of cancer therapy-biologic response modifiers (FACT-BRM) instrument. Value Health 8(2):117\u2013127","journal-title":"Value Health"},{"key":"2196_CR30","doi-asserted-by":"crossref","unstructured":"Deininger MW. Chronic myeloid leukemia: an historical perspective (2008) Hematology Am Soc Hematol Educ Program 418","DOI":"10.1182\/asheducation-2008.1.418"},{"issue":"6","key":"2196_CR31","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3109\/10428194.2011.560310","volume":"52","author":"Z Aziz","year":"2011","unstructured":"Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A (2011) Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 52(6):1017\u20131023","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2196_CR32","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2009","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al (2009) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554\u20134560","journal-title":"Blood"},{"issue":"4","key":"2196_CR33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","volume":"21","author":"KM Phillips","year":"2013","unstructured":"Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ et al (2013) Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 21(4):1097\u20131103","journal-title":"Support Care Cancer"},{"issue":"7","key":"2196_CR34","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","volume":"27","author":"F Efficace","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL et al (2013) Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 27(7):1511\u20131519","journal-title":"Leukemia"},{"key":"2196_CR35","author":"F Efficace","year":"2013","unstructured":"Efficace F, Rosti G, Cottone F, Breccia M, Castagnetti F, Iurlo A et al (2013) Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leuk Res. doi: 10.1016\/j.leukres.2013.07.003 , [Epub ahead of print] PubMed PMID: 23906625","journal-title":"Leuk Res"},{"issue":"1","key":"2196_CR36","first-page":"22","volume":"92","author":"F Efficace","year":"2013","unstructured":"Efficace F, Rosti G, Aaronson N, Cottone F, Angelucci E, Molica S et al (2013) Patient versus physician symptom and health status reporting in chronic myeloid leukemia. Haematologica 92(1):22\u201324, [Epub ahead of print] PubMed PMID: 24241488","journal-title":"Haematologica"},{"key":"2196_CR37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1477-7525-11-167","volume":"11","author":"I Hirji","year":"2013","unstructured":"Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E et al (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective. Health Qual Life Outcome 11:167, PubMed PMID: 24099272","journal-title":"Health Qual Life Outcome"},{"issue":"2","key":"2196_CR38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.leukres.2012.10.021","volume":"37","author":"F Efficace","year":"2013","unstructured":"Efficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F (2013) Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res 37(2):206\u2013213","journal-title":"Leuk Res"},{"issue":"6","key":"2196_CR39","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054\u20131061","journal-title":"Leukemia"},{"issue":"1","key":"2196_CR40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000345722","volume":"130","author":"MH Almeida de","year":"2013","unstructured":"de Almeida MH, Pagnano KB, Vigorito AC, Lorand-Metze I, de Souza CA (2013) Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort. Acta Haematol 130(1):16\u201322","journal-title":"Acta Haematol"},{"key":"2196_CR41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2196_CR42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","volume":"28","author":"PS Brucker","year":"2005","unstructured":"Brucker PS, Yost K, Cashy J, Webster K, Cella D (2005) General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G). Eval Health Prof 28(2):192\u2013211","journal-title":"Eval Health Prof"},{"issue":"6","key":"2196_CR43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","volume":"107","author":"F Efficace","year":"2012","unstructured":"Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M et al (2012) Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 107(6):904\u2013909","journal-title":"Br J Cancer"},{"issue":"5","key":"2196_CR44","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/cncr.26391","volume":"118","author":"E Jabbour","year":"2012","unstructured":"Jabbour E, Saglio G, Hughes TP, Kantarjian H (2012) Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer 118(5):1181\u20131191","journal-title":"Cancer"},{"issue":"9","key":"2196_CR45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","volume":"91","author":"F Efficace","year":"2012","unstructured":"Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G et al (2012) Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. Ann Hematol 91(9):1371\u20131381","journal-title":"Ann Hematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-014-2196-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2196-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T03:59:30Z","timestamp":1648612770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-014-2196-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,20]]},"references-count":45,"alternative-id":["2196"],"URL":"https:\/\/doi.org\/10.1007\/s00520-014-2196-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,20]]}}}